미국 Accegen은 생명과학 연구와 의약품 개발을 지원하기 위해 다양한 세포주와 생물학적 제품을 제공하는 바이오 제품 제조 기업입니다.
제품 설명
NOMO-1
제품 번호
ABC-TC1314
제품 특징
A human monocytic leukemia cell line, NOMO-1, was established from a female with acute monocytic leukemia (M5a). NOMO-1 exhibits promonocytic characteristics, and its differentiation into macrophage-like cells was induced by using 12-o-tetradecanoyl phorbol-13-acetate (TPA). Following the addition of TPA, fibronectin was observed in NOMO-1 cells, and the culture medium showed increased levels of Interleukin-1 (IL-1) α and IL-1 β.
TPA also stimulated the secretion of tissue factors from NOMO-1 cells. TPA enhanced the secretion of tissue factor from NOMO-1 cells, while warfarin (1ng/ml) inhibited the secretion. Moreover, the activity of the plasminogen activator (PA) gradually increased during the 17-day culture period. NOMO-1 can be cultured in RPMI1640 medium with 10% FBS.
Why choose NOMO-1 from AcceGen?
NOMO-1, our cell product, underwent various tests and analyses to ensure its quality. We evaluated NOMO-1’s cell morphology and cell viability. Its growth performance was tested under culture conditions without antibiotics and antimycotics. Furthermore, we tested NOMO-1 for the absence of HIV-1, HIV-2, HBV, HCV, HTLV-1, and HTLV-2, as well as microbial contaminants such as fungi, bacteria, and mycoplasma. These rigorous assessments confirm the reliability and safety of NOMO-1 as a cell line for various applications.
NOMO-1 is a useful tool to study the differentiation and maturation of monocytes and identify AML-specific antigens for therapeutic targeting. NOMO-1, utilized as a model, exhibits aberrant expression of NANOG, an NKL homeobox gene that functions as a stem cell factor and is specifically expressed in hematopoietic progenitor cells.
NOMO-1 is also employed in drug development and investigating potential signaling pathways. It expresses granulocyte colony-stimulating factor (G-CSF) and responds to exogenous G-CSF. In the NOMO-1 model, it has been observed that exogenous G-CSF increases sensitivity to DNA topoisomerase II-targeting drugs and upregulates the expression of transferrin receptor (TfR). Additionally, NOMO-1 serves as a valuable model for studying drug resistance. It has been confirmed to be resistant to pinometostat (EPZ-5676), a selective inhibitor of DOT1L.
Accegen의 모든 제품들을 만나 보세요!
PRODUCTS
MSDS
온라인 견적